Biochemist is rapidly moving towards its main goal - import substitution in the Russian pharmaceutical industry

In 2019, the company received more than 20 registration certificates for medicines of various forms and groups.

JSC Biochemist is actively developing and implementing a policy of import substitution. Every year, the plant launches dozens of new medicines, providing consumers with effective, safe and high-quality medicines at affordable prices.

The main task for the company in the near future, as before, will be the production of innovative antibiotics available to the citizens of our country.

In the near future, Biochemist JSC will launch the antibacterial drug Cefoperazone + Sulbactam on the pharmaceutical market, which is an effective combination of the third-generation cephalosporin cefoperazone with the beta-lactamase inhibitor sulbactam. The drug will be available in powder form for injection preparation.

When releasing an antibacterial drug, the company will use all stages of drug production.

This broad-spectrum antibiotic is effective against most Gram-positive microorganisms and has high activity against Gram-negative bacteria. And this is a very important factor in the rapid increase in resistance among gram-negative pathogens of nosocomial infections, which causes great concern among the medical community. Thus, more than 50 percent of Pseudomonas aeruginosa strains and more than 60 percent of Acinetobacter strains in hospitals in various regions of Russia are extremely resistant to antibiotics. More than 70 percent of enterobacteria are resistant to widely used antibiotics.

The main difference between Cefoperazone + Sulbactam registered by JSC Biochemik and other drugs in this group is its high antibacterial resistance and easy tolerance to its effects by patients.

This is how the expert speaks about the drug Cefoperazone + Sulbactam.

Sergey Vladimirovich Matkevich, Ph.D., Head of the Surgical Outpatient Department, Gazprom Transgaz Moscow Center for Diagnostics and Rehabilitation, LLC:

The advantage of the combination of cephalosporins with sulbactam is to expand the antimicrobial spectrum due to gram-negative bacteria, which makes it possible to fight hospital infections more effectively. Studies have shown that the sensitivity of some enterobacteria that cause nosocomial infections turned out to be 5 times higher to the action of a combination than to monotherapy. The advantage of such a combination in intra-abdominal infections, sepsis, pyelonephritis, in the prevention of postoperative complications has been experimentally revealed. In addition, the synergism of sulbactam and cefoperazone makes it possible to reduce the concentrations of the components to achieve a pronounced and persistent antimicrobial effect.

Of course, Russian pharmaceutical companies need to prioritize the production of such significant and sought-after drugs. The initiatives of the Biochemist JSC plant to develop and create fully Russian-made antibiotics are an example of the competent implementation of an import substitution strategy.

In addition to antibiotics, the list of drugs registered by JSC Biochemik also includes solutions for intravenous administration – Cisatrocurium bezilate (a drug for muscle relaxation) and Tranixamic acid, a drug used to treat or prevent excessive blood loss from injury, surgery, and hemophilia.

Practitioners emphasize the importance of manufacturing these drugs.

Irina Vyacheslavovna Savelyeva, MD, Professor, Head of the Department of Obstetrics and Gynecology No. 1, Omsk State Medical University:

Obstetric bleeding continues to be one of the top three causes of maternal morbidity and mortality, along with infectious complications and hypertensive disorders during pregnancy. In about one in five cases, the bleeding becomes massive, which threatens the health and life of the mother, increases the need for resuscitation and transfusion of blood components, which, in turn, leads to an increase in financial costs for the treatment and rehabilitation of the patient. Tranexamic acid belongs to antifibrinolytic agents. It has local and systemic hemostatic effects in bleeding associated with increased fibrinolysis, as well as anti-inflammatory, antiallergic, anti-infective and antitumor effects, its own analgesic activity and a potentiating effect on the analgesic activity of opiates.  Moreover, the use of tranexamic acid can be effective in preventing not only blood loss during surgery, but also postpartum bleeding. Additional advantages of tranexamic acid, such as antifibrinolytic activity, which is ten times higher than that of aminocaproic acid, the possibility of combination with low molecular weight heparins and high safety make preparations based on it indispensable in gynecological practice.

Olga Valeryevna Konstantinova, PhD, BPSC RAS:

Cisatracurium bezilate is a modern muscle relaxant. Its advantages include a high rate of onset of action, an organ-independent metabolism, the absence of dose-dependent histamine release and, consequently, cardiovascular stability, which ultimately determines the predictability of the duration of action and the clinical safety of the drug. The peculiarity of its metabolism (non-enzymatic nature) allows it to be used in the treatment of patients with hepatic and renal insufficiency. The possibility of using cisatracurium during prolonged vertebrological surgeries in children and adolescents is also an important advantage of the drug.

One of the strategically important tasks for Biochemik is the implementation of a nationwide program to combat oncological diseases within the framework of the President's instructions. The plant has started developing an innovative project to create cancer drugs, which will be implemented in the near future.

It is no secret that the percentage of deaths from cancer is one of the highest not only in our country, but throughout the world. Every year, new and different means of combating cancer appear. Including medications. It is important for Russia that they are of domestic production: dependence on foreign supplies is dangerous, especially given the current difficult international situation. The Head of State set the task for the Ministry of Health and the Ministry of Industry of the Russian Federation to develop this area, actively involving science and the domestic pharmaceutical industry in solving a difficult task. Biochemist has been actively involved in this work. As early as 2020, the company will begin pharmaceutical development and synthesis of 17 anticancer drug molecules.  The drugs will be aimed at combating almost all types of cancer (thyroid and breast cancer, skin melanoma, brain cancer, etc.)

Irina Evgenievna Guseva, KMN, BPSC RAS:

Cancer-related deaths in Russia are still very high. However, it is possible to reduce it, prolong the patient's life, and improve its quality by increasing the availability of innovative medicines. In addition, there are nosologies, as well as certain groups of cancer patients, in the treatment of which only innovative targeted anticancer drugs can be effective. This category, in particular, includes patients suffering from kidney cancer. The research work carried out at the Biochemist plant and its modern technological capabilities will allow us to raise the possibilities of cancer therapy to a new level.

In addition, the list of registered drugs of JSC Biochemik includes Gepreda (lyophilizate), Clarithromycin, Dexketoprofen, Cefepime, Atracurium bezilate, etc.

In total, in 2019, Biochemist JSC received more than 20 registration certificates for the latest medicines that had not previously been produced in our country. More than 40 drugs are planned to be registered next year.

In the future, the company will have one of the largest portfolios of modern drugs of various forms of release.